[{"id":"95f1caad-e2a9-49d6-a746-27399eb328fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04439357","created_at":"2021-01-18T21:22:14.497Z","updated_at":"2024-07-02T16:35:19.658Z","phase":"Phase 2","brief_title":"Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)","source_id_and_acronym":"NCT04439357","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • GNA11","pipe":" | ","alterations":" GNAQ mutation • GNA11 mutation","tags":["GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation • GNA11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 02/25/2016","start_date":" 02/25/2016","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-02-13"},{"id":"fbb7d698-9f0e-4c48-8128-78efb036d790","acronym":"","url":"https://clinicaltrials.gov/study/NCT01328106","created_at":"2021-01-18T05:24:47.264Z","updated_at":"2024-07-02T16:37:15.572Z","phase":"Phase 2","brief_title":"Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma","source_id_and_acronym":"NCT01328106","lead_sponsor":"GlaxoSmithKline","biomarkers":" GNAQ • GNA11","pipe":" | ","alterations":" GNAQ mutation • GNA11 mutation","tags":["GNAQ • GNA11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation • GNA11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 08/01/2011","primary_completion_date":" 08/01/2011","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2017-12-12"},{"id":"b28bc4bf-2724-470d-a200-8e1a03612399","acronym":"","url":"https://clinicaltrials.gov/study/NCT01143402","created_at":"2021-01-17T17:53:31.374Z","updated_at":"2024-07-02T16:37:19.584Z","phase":"Phase 2","brief_title":"Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye","source_id_and_acronym":"NCT01143402","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GNAQ • GNA11 • CYP1A2","pipe":" | ","alterations":" GNAQ mutation","tags":["GNAQ • GNA11 • CYP1A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GNAQ mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Koselugo (selumetinib) • dacarbazine"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2017-07-26"}]